We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
In Vivo is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Specialty generics and proprietary pharmaceuticals company Barr Laboratories has agreed to buy women's health care pharmaceutical specialist Duramed Pharmaceuticals in a stock swap. Barr says it will issue approximately 8.25mm of its common shares, worth $588.5mm (based on Barr's average trading price). Duramed stockowners get one Barr share for every 3.9 Duramed common held.
Deal Industry
Pharmaceuticals
Pharmaceuticals
Generic Drugs
Deal Status
Final
Deal Type
Acquisition
Full Acquisition
Includes Contract
Payment Includes Stock
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?